Dyslipidemia
Annals of Internal Medicine · 2023-06 · 176 (6) · ITC81-ITC96
DOI: 10.7326/aitc202306200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Internal Medicine, 2023-06. Verfasst von Marios Arvanitis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland (M.A., C.J.L.). Hauptthemen laut MEDLINE: Dyslipidemias, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Dyslipidemia is an important risk factor for coronary artery disease and stroke. All persons with dyslipidemia should be advised to focus on lifestyle interventions, including regular aerobic exercise, a healthy diet, maintenance of a healthy weight, and abstinence from smoking. In addition to lifestyle interventions, lipid-lowering therapy should be considered for persons at moderate to high risk for atherosclerotic cardiovascular disease based on validated risk equations. Statin therapy is the first-line medical treatment for dyslipidemia due to its effectiveness and favorable adverse effect profile, but newer treatments provide additional tools for clinicians to effectively treat dyslipidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, Baltimore, Maryland (M.A., C.J.L.).
ORCID-Profile: Charles J Lowenstein
Zitieren
APA
Arvanitis, M., & Lowenstein, C. J. (2023). Dyslipidemia. Annals of Internal Medicine, 176(6), ITC81-ITC96. https://doi.org/10.7326/aitc202306200
Vancouver
Arvanitis M, Lowenstein CJ. Dyslipidemia. Annals of Internal Medicine. 2023;176(6):ITC81-ITC96. doi:10.7326/aitc202306200
BibTeX
@article{Arvanitis2023,
author = {Arvanitis, Marios and Lowenstein, Charles J},
title = {Dyslipidemia},
journal = {Annals of Internal Medicine},
year = {2023},
volume = {176},
number = {6},
pages = {ITC81--ITC96},
doi = {10.7326/aitc202306200}
}
EUVIMED